All In Biotech

Drug Trial Radar · NCT01819727

An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165

A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety & Tolerability of an Induction, Titration, and Maintenance Dose Regimen of BMN 165 Self Administered by Adults With PKU Not Previously Treated With BMN 165

Last checked: Nov 20, 2026Latest source record: Feb 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 261 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

261

Actual

Start

May 2013

Primary completion

Nov 25, 2015

Study completion Nov 25, 2015

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Mar 28, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in patients 18 to 70 years old with hyperphenylalaninemia due to PKU. Study BMN 165-301 is a Phase 3, open-label, randomized study designed to further characterize the safety of BMN 165 during two induction, titration, and maintenance dose regimens in adults with PKU who have not had previous exposure to BMN 165 (naive). Subjects will be randomized (1:1) to titrate up to one of two dose regimens. Other key features of this study are the dose regimens chosen for induction and titration; the study duration; self administration of study drug; and the chosen tertiary objectives.

Conditions

  • Phenylketonuria

Interventions

  • BMN 165Drug

    After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Hypersensitivity Adverse ReactionTime frame: baseline and 36 weeks

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Altman Clinical and Translational Research Institute

    La Jolla, California

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • The Children's Hospital Colorado

    Aurora, Colorado

  • University of Florida Clinical Research Center

    Gainesville, Florida

  • University of Miami Health System

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Emory Universty

    Decatur, Georgia

  • Ann and Robert H Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Riley Children's Hospital

    Indianapolis, Indiana

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Weisskopf Child Evaluation Center / University of Louisville

    Louisville, Kentucky

  • Boston Children's Hospital

    Boston, Massachusetts

  • Wayne State University

    Detroit, Michigan

  • University of Missouri

    Columbia, Missouri

  • Washington University Center for Applied Research Sciences

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Cooper Health Systems

    Camden, New Jersey

  • Atlantic Health System - Morristown Medical Center

    Morristown, New Jersey

  • Albany Medical College

    Albany, New York

  • Icahn School of Medicine at Mount Sinai Medical Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • University Hospital Cleveland, Case Medical Center

    Cleveland, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Oregon Health & Science University

    Portland, Oregon

  • St. Christopher's Hospital for Children

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Health Science at Houston

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Washington Medical Center

    Seattle, Washington

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.